Spasticity Treatment Market

Spasticity Treatment Market Snapshot

According to Future Market Insights (FMI) analysis in a recent market survey, the global spasticity treatment market was valued at USD 12.2 Billion in 2022 and is set to reach USD 28.4 Billion by 2033.

Market Outlook:

Data Points	Market Insights
Market Value 2022	USD 12.2 Billion
Market Value 2023	USD 13.1 Billion
Market Value 2033	USD 28.4 Billion
CAGR 2023 to 2033	8.1%
Share of Top 5 Countries	54.0%
Key Players	Medtronic Plc; Piramal Enterprises Ltd.; AbbVie, Inc. (Allergan); Ipsen Pharma; F. Hoffmann-La Roche Ltd; GlaxoSmithKline plc; Pfizer Inc.; Elite Pharmaceuticals Inc.; Orient Pharma; Acorda Therapeutics, Inc.; Sun Pharmaceutical Industries Ltd; Novartis AG (Alcon); Teva Pharmaceutical Industries Ltd; Zydus Cadila Healthcare Ltd.; Beximco Pharmaceuticals Ltd; Merz Pharma; Thought Technology Ltd.; UltraCare PRO; Invacare Corporation; ATI Physical Therapy; P.T. Services Rehabilitation, Inc.; Banner Health.

Spasticity is one of many clinical traits or motor behavior that can appear following injury to the area of the brain or spinal cord that regulates voluntary movements. Upper motor neuron syndrome is the term used to describe these symptoms taken together.

One of the key factors promoting the growth of the spasticity treatment market is the rising prevalence of neuro-musculoskeletal disorders. Spasticity is becoming more common as chronic neuro-musculoskeletal illnesses become more common on a global scale.

• For instance, the multiple sclerosis Trust estimates that in 2020, there were around 2.5 million multiple sclerosis patients worldwide. External factors that harm the spinal cord or the brain directly contribute to spinal cord injury and traumatic brain injury, respectively.

The high prevalence of these illnesses worldwide is a result of an increase in slips, accidents, assaults, and other incidents. A diagnosis of spasticity was made in more than 50% to 60% of these cases. The global market thus benefits from the rising prevalence of various chronic disorders due to the close association between the aforementioned chronic conditions and spasticity. This rising incidence will drive market expansion over the forecast period.

Overall, the adoption of spasticity treatment in healthcare facilities, which will boost the market in the coming years.

Sales Analysis of Spasticity Treatment Market from 2012 to 2022 Vs Market Outlook for 2023 to 2033

Sales of the global market grew at a CAGR of 5.4% between 2012 and 2022. Spasticity treatment market contributes 29.6% revenue share to the global neurodegenerative disease treatment market value at USD 41.2 Billion in 2022.

The ageing population is one of the primary factors fueling the market for spasticity treatments.

• According to projections from the World Health Organization (WHO), the number of people in the world who are 60 years of age or older is expected to increase from 1 billion in 2020 to 1.4 billion by 2050. By 2050, there will be twice as many people in the world who are 60 years or older (2.1 billion), compared to 2020.

Age-related changes in the brain, traumas like stroke or traumatic brain damage, addiction, and diseases like multiple sclerosis (MS), stroke, and brain tumours, among others, can all have a substantial impact on brain health, which will increase the prevalence of spasticity and its related indications, which will boost the market for spasticity treatments.

Advanced procurement operations provide businesses and manufacturers with chances to develop and expand their clientele to buyers and suppliers that collaborate to create cutting-edge products that increase sales and profits for all parties. By implementing several techniques into their processes, they adopt an integrated approach to creating new goods and procedures.

Different key strategies such as new product launches, acquisitions, collaborations, and expansion are being used by companies and different manufacturers for the advancement and development of new products and therapies.

• For instance, In August 2020, Teva Pharmaceuticals & Biopharmaceutical Company Alvotech collaborated to expand their sales in the USA.
• Ipsen and Accent Therapeutics (Accent) signed an exclusive global collaboration agreement to conduct research, develop, produce, and market the products on October 18, 2021.

Considering this, FMI expects the global market to grow at a CAGR of 8.1% through the forecasted years.

What are the Key Opportunities for players in the Spasticity Treatment Market?

Cognitive knowledge and evaluation of everyday things and issues is one of the most important indicators of a person's mental health and ability to think and act in life-or-death situations.

The brain is a sophisticated organ that has a significant impact on one's overall health and well-being. Brain health can be significantly impacted by ageing-related changes in the brain and traumas like stroke or traumatic brain injury. While certain factors that affect brain health cannot be avoided, there are other lifestyle changes that can be beneficial.

Since they improve brain glucose metabolism and reduce the risk of mental disorders, improved brain and mental fitness is becoming more and more in demand, opening up new treatment options for spasticity.

Increased testing of combination therapies in patients will pave the way for new drug discoveries and treatment options, ultimately leading to the introduction of new products into the market.

Which Factors Could Possibly Restrain the Growth of Spasticity Treatment Market?

For the spasticity treatment process, there is a requirement of skilled specialists such as physiatrists, neurologists, rehabilitation nurses, physical and occupational therapists, speech and language pathologists, psychologists, social workers, recreational therapists, etc.

The non-availability and limited number of such well-trained specialists can have an adverse impact on the treatment of patients with spasticity and also lower the growth of the organizations that are involved in the treatment. Due to these factors, the quality of services can get affected, and this will ultimately have a negative impact on the growth of the spasticity treatment market.

The dearth of skilled professionals in these fields can lower the quality of services offered, ultimately affecting the growth of the spasticity treatment market.

These factors are expected to hamper revenue growth of the global market over the forecast period.

Country-wise Insights

What Makes the USA Dominate the Global Market?

The USA market dominated the global market with value of around USD 3.63 Bilion in 2022 and is expected to register a CAGR of 8.3% during the forecast period.

The high prevalence of spasticity in the United States will accelerate the acceptance of various treatment alternatives.

• According to the MERZ PHARMACEUTICALS, Spasticity is estimated to affect more than 12 million people worldwide and approximately 50,000 persons in the United States yearly. 38% of stroke survivors develop spasticity within a year of their initial stroke, while the prevalence of post-stroke spasticity overall (the percentage of people who experience it in the general population) is roughly 0.2%.

Due to the high prevalence, more treatments, including over-the-counter products, will experience a high adoption rate among patients. The demand for spasticity treatment will increase due to high prevalence, which will drive the expansion of the market.

Why is Germany considered to be a Lucrative Region for Spasticity Treatment Market in Europe?

Germany dominated the European market for spasticity treatment and accounted for around 22.3% of the regional market share in 2022.

Increasing technological advancements in spasticity treatment therapies in Germany is driving the overall Europe spasticity treatment market.

Virtual reality technology can be used to provide immersive therapy experiences for patients with spasticity. These experiences can help patients to improve their motor skills and reduce spasticity through interactive and engaging activities. This therapy has been found to be effective in reducing spasticity in patients with cerebral palsy, multiple sclerosis, and other neurological conditions.

The safe and successful spasticity treatment therapies in Germany will influence other European countries to also opt for this treatment method, ultimately expanding the overall market.

What Makes China an Emerging Market for Spasticity Treatment?

China is projected to be the most attractive market in the East Asia region, and is expected to grow over a significant CAGR of 7.7% during the forecast duration.

The spasticity treatment market in China is expected to grow significantly in the coming years due to several factors.

One of the main factors driving the growth of the spasticity treatment market in China is the increasing awareness of the condition among the general public and healthcare professionals. As more people become aware of the condition, they are more likely to seek treatment, which is leading to increased demand for treatments for spasticity.

Another factor contributing to the growth of the spasticity treatment market in China is the increasing availability of advanced medical technologies and treatments. China has made significant investments in its healthcare infrastructure, and many new hospitals and clinics have been built in recent years. This has allowed for the introduction of advanced treatments such as botox injections and surgery, which were not widely available in the past.

Category-wise Insights

Why Treatment type Is Largely Adopted for Spasticity?

The treatment segment utilizing drugs, physical therapy, Botulinum toxin, surgical treatment and others treatment options held the major chunk of about 68.4% in global market by the end of 2022.

With advances in medical technology, it has become easier to diagnose spasticity accurately. This has led to more people being diagnosed with the condition, which in turn has increased the demand for treatment. There is now more awareness about spasticity among healthcare providers, patients, and the general public. This has helped to reduce the stigma associated with the condition and encouraged more people to seek treatment.

There have been significant advances in the development of new treatments for spasticity, including medications, physical therapy, and surgical procedures. These treatments can help to reduce spasticity and improve overall quality of life for people with the condition.

Why Cerebral Palsy Is Dominating Indication for Spasticity?

The Cerebral Palsy segment held the major chunk of about 14.4% in global market by the end of 2022.

Increased awareness of cerebral palsy and improved diagnostic techniques have led to more accurate diagnosis and reporting of cases, contributing to the observed increase in prevalence. Certain risk factors, such as maternal infections during pregnancy, prematurity, and low birth weight, have become more common in recent years. This has contributed to the increase in the incidence of cerebral palsy and spasticity.

Which Distribution Channel Dominates the Global Market in 2022?

The hospital pharmacies segment accounted for revenue share of 38.3% in the global market at the end of 2022.

Hospital pharmacies offer convenient access to treatment options, with many providing over-the-counter and prescription medications for a range of conditions, including cerebral palsy, multiple sclerosis among others. Patients can typically purchase these treatments without an appointment, making it more convenient for them to manage their condition.

Overall, hospital pharmacies offers a convenient and accessible distribution channel for spasticity treating products, making it the largest channel for these treatments.

Which Service Providers Dominates the Global Market in 2022?

The hospitals segment accounted for revenue share of 37.1% in the global market at the end of 2022.

Hospitals typically have access to a wide range of specialized medical professionals, including neurologists, physiatrists, orthopedic surgeons, and physical therapists, who can collaborate to provide comprehensive spasticity treatment.

Overall, hospitals are a leading segment for spasticity treatment because they provide access to specialized medical professionals, advanced diagnostic tools, multimodal treatments, specialized equipment and facilities, and both inpatient and outpatient services.

Competitive Landscape

Key players in the market are focused on increase their product portfolio to strengthen their position in the spasticity treatment market, and also to expand their footprint in emerging markets. The key strategy adopted by manufacturers to gain competitive edge in the market are the pricing strategies, market strategies, technological advancements, regulatory compliance and acquisition of other companies to expand their business.

For instance:

• In August 2022, Medtronic completed the acquisition of Affera. This acquisition gave Medtronic access to Affera's Prism-1™ cardiac mapping and navigation platform, which is compatible with Medtronic's therapeutic catheters as well as a number of competing technologies.
• In January 2020, Botox manufacturer Allergan received regulatory approval to use the drug to treat young patients with upper limb spasticity.

Similarly, recent developments have been tracked by the team at Future Market Insights related to companies in the spasticity treatment market space, which are available in the full report

Scope of the Spasticity Treatment Report

Attribute	Details
Forecast Period	2023 to 2033
Historical Data Available for	2012 to 2022
Market Analysis	USD Million for Value
Key Regions Covered	North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East and Africa (MEA)
Key Countries Covered	USA, Canada, Brazil, Mexico, Argentina, Germany, United Kingdom, France, Italy, Spain, Russia, BENELUX, Nordics, India, Thailand, Indonesia, Malaysia, Philippines, Vietnam, China, Japan, South Korea, Australia, New Zealand, Türkiye, South Africa, North Africa and GCC Countries
Key Segments Covered	Diagnosis & Treatment Type, Indication, Distribution Channel, Service Providers, and Region
Key Companies Profiled	Medtronic Plc; Piramal Enterprises Ltd.; AbbVie, Inc. (Allergan); Ipsen Pharma; F. Hoffmann-La Roche Ltd; GlaxoSmithKline plc; Pfizer Inc.; Elite Pharmaceuticals Inc.; Orient Pharma; Acorda Therapeutics, Inc.; Sun Pharmaceutical Industries Ltd; Novartis AG (Alcon); Teva Pharmaceutical Industries Ltd; Zydus Cadila Healthcare Ltd.; Beximco Pharmaceuticals Ltd; Merz Pharma; Thought Technology Ltd.; UltraCare PRO; Invacare Corporation; ATI Physical Therapy; P.T. Services Rehabilitation, Inc.; Banner Health
Report Coverage	Market Forecast, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, Strategic Growth Initiatives
Customization & Pricing	Available upon Request

Key Segments Covered in Spasticity Treatment Industry Research

By Diagnosis & Treatment Type:

• Diagnosis
  • Inpatient
  • Outpatient
• Treatment Type
  • Drug
    • Baclofen
    • Tizanidine
    • Dantrolene sodium
    • Diazepam
    • Clonazepam
    • Gabapentin
  • Physical Therapy
  • Botulinum injection
  • Surgery Treatment
  • Other Treatment
• Devices
  • Reciprocal EMG-Triggered Stimulation
  • Transcutaneous Electrical Nerve Stimulation
  • Bracing and Cuff
  • Leg lifter
  • Cane and Crunches
  • Wheelchair
  • Others

By Indication:

• Cerebral Palsy
• Multiple Sclerosis
• Amyotrophic Lateral Sclerosis
• Hereditary Spastic Paraplegias
• Periventricular Leukomalacia
• Metabolic Diseases
• Traumatic Brain Injury
• Spinal Cord Injury
• Stroke
• Multiple System Atrophy
• Stiff-Person Syndrome
• Infectious Transvers Myelitis
• Encephalopathy
• Brain Tumor
• Krabbe Disease
• Johns Hopkins Disease

By Distribution Channel:

• Hospitals Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies

By Service Providers:

• Hospitals
• Ambulatory Surgical Centers
• Home Care Settings
• Specialty Clinics
• Diagnostic Centers

By Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa (MEA)

Frequently Asked Questions

How much is the global market currently worth in 2022?

The global market is valued around USD 12.2 Billion in 2022.

What is the global market estimated reach in 2023?

The global market estimates for 2023 is around USD 13.1 Billion.

What is the sales forecast for the global market till 2033?

The global market is set to reach USD 28.4 Billion by the end of 2033, with sales revenue expected to be 8.1% CAGR through 2033.

Which region dominated the global market in 2022?

North America dominated the global market in 2022 with the USA being the leading contributor in the North American region.

What are key opportunities in the global market?

Rising demand for improved brain and mental fitness and improving healthcare infrastructure to offer lucrative growth opportunities for the market players to grow.

Which Indication segment will garner significant value share by 2022?

Cerebral palsy segment dominated the global market in 2022 with 14.4% revenue share and is expected to lead in 2023 as well.

What are the top countries driving demand for the market?

The USA, India, China, Germany and United Kingdom are the top countries that are driving the demand for the spasticity treatment globally.

What was the last ten year’s CAGR for the global market?

From 2012 to 2022, the market for spasticity treatment expanded at the rate of 5.4%.

Which are the leading companies in the spasticity treatment market?

Allergan plc. (AbbVie), F. Hoffmann-La Roche Ltd, Pfizer Inc., Medtronic Plc, GlaxoSmithKline plc, are few key players within the global market.

What is the China market outlook?

China is projected to grow with CAGR of 7.7% over the forecast duration.